title: The hip fracture best practice tariff: early surgery and the implications for MRSA screening and antibiotic prophylaxis.
abstract: BACKGROUND
  In April 2010, the Department of Health introduced the hip fracture best practice. Among the clinical criteria required to earn remuneration is surgery within 36 h of admission. However, early surgery may mean that methicillin-resistant Staphylococcus aureus (MRSA) colonisation status is not known before surgery, and therefore, appropriate antibiotic prophylaxis may not be administered. In view of this, our department's policy is to administer an additional dose of teicoplanin to patients with unknown MRSA status along with routine antimicrobial prophylaxis.
  
  
  OBJECTIVE
  The purpose of this study was to provide a safe and effective antimicrobial prophylaxis for hip fracture patients.
  
  
  METHODS
  We prospectively collected details of demographics and antimicrobial prophylaxis for all patients admitted with a hip fracture in November 2011. This was repeated in February 2012 after an educational and advertising drive to improve compliance with departmental antimicrobial policy. Microbiology results were obtained from the hospital microbiology database. A cost-benefit analysis was undertaken to assess this regime.
  
  
  RESULTS
  A total of 144 hip fracture patients were admitted during the 2 months. The average admission to surgery time was 32 h, and the average MRSA swab processing time was 35 h. 86 % of patients reached theatre with unknown MRSA status. Compliance with the departmental antimicrobial policy improved from 25 % in November 2011 to 76 % in February 2012. Potential savings of £ 40,000 were calculated.
  
  
  CONCLUSIONS
  With best practice tariff resulting in 86 % of patients reaching theatre with unknown MRSA status, we advocate an additional single dose of teicoplanin to cover against possible MRSA colonisation.
authors.affiliation: Department of Orthopaedic Surgery, Kings Mill Hospital, Mansfield Road, Sutton-In-Ashfield, Nottinghamshire, NG17 4JL, UK, Davidjbryson@hotmail.com.
authors.forename: David J
authors.initials: DJ
authors.lastname: Bryson
authors.forename: Abhinav
authors.initials: A
authors.lastname: Gulihar
authors.forename: Randeep S
authors.initials: RS
authors.lastname: Aujla
authors.forename: Grahame J S
authors.initials: GJ
authors.lastname: Taylor
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D002353:Carrier State / Q000175:diagnosis* / Q000382:microbiology; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D005260:Female; D019983:Guideline Adherence; D006620:Hip Fractures / Q000601:surgery*; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D012052:Reimbursement, Incentive; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D017334:Teicoplanin / Q000627:therapeutic use*; D013997:Time Factors; D061665:Time-to-Treatment
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin
references.citation: Eur J Clin Microbiol Infect Dis. 1999 Feb;18(2):113-9
references.pmid: 10219575
references.citation: Int Orthop. 2004 Feb;28(1):16-20
references.pmid: 12750847
references.citation: Clin Microbiol Infect. 2005 Oct;11(10):775-7
references.pmid: 16153250
references.citation: J Bone Joint Surg Br. 2008 Jun;90(6):770-7
references.pmid: 18539671
references.citation: J Bone Joint Surg Br. 2006 Jun;88(6):812-7
references.pmid: 16720779
references.citation: J Bone Joint Surg Br. 2005 Jun;87(6):844-50
references.pmid: 15911671
references.citation: J Antimicrob Chemother. 2002 Aug;50(2):171-5
references.pmid: 12161396
references.citation: Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):35-8
references.pmid: 16424973
references.citation: J Bone Joint Surg Am. 1973 Sep;55(6):1251-8
references.pmid: 4585947
references.citation: Clin Infect Dis. 2007 Apr 1;44(7):921-7
references.pmid: 17342642
references.citation: Br Med J. 1979 Mar 17;1(6165):707-9
references.pmid: 373841
references.citation: Int J Qual Health Care. 2007 Jun;19(3):170-6
references.pmid: 17309897
references.citation: Infect Control Hosp Epidemiol. 2007 Jul;28(7):853-9
references.pmid: 17564989
references.citation: J Bone Joint Surg Br. 2005 Jun;87(6):749-54
references.pmid: 15911652
references.citation: Acta Orthop Belg. 2009 Apr;75(2):252-7
references.pmid: 19492566
references.citation: J Antimicrob Chemother. 2006 Apr;57(4):589-608
references.pmid: 16507559
references.citation: J Bone Joint Surg Br. 2011 Apr;93(4):548-51
references.pmid: 21464498
references.citation: J Orthop Surg Res. 2011 May 23;6:25
references.pmid: 21605456
references.citation: Clin Microbiol Infect. 2010 Dec;16(12):1747-53
references.pmid: 20331684
references.citation: Injury. 2013 Jun;44(6):726-9
references.pmid: 23010072
references.citation: Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):793-6
references.pmid: 7889947
references.citation: J Hosp Infect. 1999 Oct;43(2):115-22
references.pmid: 10549311
references.citation: J Antimicrob Chemother. 1998 Mar;41(3):329-40
references.pmid: 9578159
references.citation: J Clin Microbiol. 2003 Jul;41(7):3163-6
references.pmid: 12843058
references.citation: Cochrane Database Syst Rev. 2011 Dec 07;(12):CD006354
references.pmid: 22161402
references.citation: J Hyg (Lond). 1984 Dec;93(3):505-29
references.pmid: 6512253
references.citation: Clin Infect Dis. 2004 Sep 15;39(6):776-82
references.pmid: 15472807
references.citation: J Antimicrob Chemother. 2004 Jun;53(6):928-35
references.pmid: 15117932
references.citation: J Bone Joint Surg Am. 2005 Mar;87(3):483-9
references.pmid: 15741611
references.citation: Clin Orthop Relat Res. 2004 Feb;(419):179-84
references.pmid: 15021151
references.citation: Lancet. 1981 Apr 11;1(8224):795-6
references.pmid: 6111670
references.citation: J Antimicrob Chemother. 1988 Jan;21 Suppl A:141-6
references.pmid: 2965126